<DOC>
	<DOCNO>NCT00616421</DOCNO>
	<brief_summary>To evaluate safety immune response Novartis MenACWY conjugate vaccine give healthy child compare licensed Meningococcal ACWY polysaccharide-protein conjugate vaccine .</brief_summary>
	<brief_title>Safety Immune Response Novartis MenACWY Conjugate Vaccine When Given Healthy Children</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>healthy 210 year age child , inclusive , nature study explain , parent legal guardian provide write informed consent available visit telephone call schedule study uptodate ageappropriate routine childhood vaccination whose parent legal guardian unwilling unable give write informed consent previous suspect disease cause N. meningitidis ; previously immunize meningococcal vaccine vaccine contain meningococcal antigen ( ) receive investigational agent vaccine within 90 day prior enrollment serious acute , chronic progressive disease epilepsy progressive neurological disease history Guillain Barr√© Syndrome history anaphylaxis , serious vaccine reaction know suspected impairment/alteration immune function , either congenital acquire result know bleed diathesis , condition may associate prolonged bleeding time Down 's syndrome know cytogenic disorder</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>vaccine</keyword>
	<keyword>child</keyword>
	<keyword>healthy</keyword>
	<keyword>meningitis</keyword>
	<keyword>meningococcal</keyword>
	<keyword>prevention meningococcal disease serogroups ACWY</keyword>
	<keyword>Menveo</keyword>
</DOC>